FDA Eases Rules for Simple COVID Rapid Tests
Published Date: 6/11/2026
Rule
Summary
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
New study, labeling, and submission requirements
Manufacturers must submit a premarket notification (510(k)) for these Class II tests and meet detailed special controls in 21 CFR 866.3982, including labeling elements, intended use limited to respiratory specimens, and clinical and analytical study requirements. Clinical evidence must include a prospective multisite study with geographically diverse samples compared to an FDA-accepted molecular comparator, and performance criteria requiring the lower bound of the two-sided 95% confidence interval for positive percent agreement to be ≥80% (or ≥70% with additional mitigations).
Faster patient access to COVID tests
The FDA has put simple point-of-care COVID-19 rapid tests into Class II, which the agency says will enhance patients' access to these tests by reducing regulatory burdens. The order is effective June 11, 2026, and the classification was applicable on March 8, 2023.
Easier market path for device makers
FDA classified simple near-patient SARS-CoV-2 tests as Class II, allowing these devices to serve as predicates for future devices and enabling sponsors to use the less-burdensome 510(k) pathway instead of premarket approval. The order is effective June 11, 2026, and the classification was applicable on March 8, 2023.
Emergency testing and rapid reporting duties
If certain actions under section 564(b)(1)(A)-(D) occur or HHS declares a public health emergency under section 319(a), manufacturers must test devices with FDA‑provided characterized samples within 30 days of notification and must include results in device labeling within 60 days; those labeling entries must remain for 3 years. FDA may also request evaluation results to be submitted within 48 hours.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-11732, Air Plan Approval; New York; New York Metropolitan Area Second Ten-Year Limited Maintenance Plan for the 2006 24-Hour PM2.5 Standard
The EPA is giving a thumbs-up to New York’s plan to keep the air clean in 10 counties around New York City for the next ten years, focusing on tiny pollution particles called PM2.5. This plan, effective July 13, 2026, helps protect people’s health without adding new costs or rules. If you live or work in the New York metro area, breathe easy knowing the air quality plan is locked in and ready to roll!
Next: 2026-11740, Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.